Oncternal Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Oncternal Therapeutics

09/08/2022 23:06

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 23 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 23 cents per share.
    * Revenue fell 78.4% to $191.00 thousand from a year ago;
analysts
expected $459.00 thousand. 
    * Oncternal Therapeutics Inc's reported EPS for the quarter
was a
loss of 23 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Oncternal Therapeutics Inc shares had risen by 4.5% this
quarter and lost 48.9% so far this year.
    * The company reported a quarterly loss of $11.74 million.
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 10:06 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.23          -0.23          Met
 Mar. 31 2022      -0.20          -0.20          Met
 Dec. 31 2021      -0.25          -0.16          Beat
 Sep. 30 2021      -0.16          -0.19          Missed